These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16804565)

  • 1. Vacuolar ATPase as a drug discovery target.
    Niikura K
    Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
    Niikura K; Takeshita N; Takano M
    J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
    Niikura K; Nakajima S; Takano M; Yamazaki H
    Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
    Niikura K; Takano M; Sawada M
    Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK; Väänänen HK
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vacuolar H+-ATPase d2 subunit: molecular characterization, developmental regulation, and localization to specialized proton pumps in kidney and bone.
    Smith AN; Jouret F; Bord S; Borthwick KJ; Al-Lamki RS; Wagner CA; Ireland DC; Cormier-Daire V; Frattini A; Villa A; Kornak U; Devuyst O; Karet FE
    J Am Soc Nephrol; 2005 May; 16(5):1245-56. PubMed ID: 15800125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
    Qin A; Cheng TS; Pavlos NJ; Lin Z; Dai KR; Zheng MH
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1422-35. PubMed ID: 22652318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.
    Laitala T; Väänänen HK
    J Clin Invest; 1994 Jun; 93(6):2311-8. PubMed ID: 8200964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vacuolar H(+)-ATPase.
    Xiao YT; Xiang LX; Shao JZ
    Int J Biochem Cell Biol; 2008; 40(10):2002-6. PubMed ID: 17897871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the osteoclast V-ATPase by small interfering RNAs.
    Hu Y; Nyman J; Muhonen P; Väänänen HK; Laitala-Leinonen T
    FEBS Lett; 2005 Sep; 579(22):4937-42. PubMed ID: 16115623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.
    Xu J; Cheng T; Feng HT; Pavlos NJ; Zheng MH
    Histol Histopathol; 2007 Apr; 22(4):443-54. PubMed ID: 17290355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
    Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
    J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases.
    Boyd MR; Farina C; Belfiore P; Gagliardi S; Kim JW; Hayakawa Y; Beutler JA; McKee TC; Bowman BJ; Bowman EJ
    J Pharmacol Exp Ther; 2001 Apr; 297(1):114-20. PubMed ID: 11259534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.
    Thudium CS; Jensen VK; Karsdal MA; Henriksen K
    Curr Protein Pept Sci; 2012 Mar; 13(2):141-51. PubMed ID: 22044152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
    Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energizing an invertebrate embryo: bafilomycin-dependent respiration and the metabolic cost of proton pumping by the V-ATPase.
    Covi JA; Hand SC
    Physiol Biochem Zool; 2007; 80(4):422-32. PubMed ID: 17508337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the vacuolar H(+)-pump with bafilomycin A1 does not induce acrosome reaction or activate proacrosin in mouse spermatozoa.
    Codelia VA; Cortes CJ; Moreno RD
    Biochem Biophys Res Commun; 2005 Dec; 337(4):1337-44. PubMed ID: 16236270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts.
    Xu J; Feng HT; Wang C; Yip KH; Pavlos N; Papadimitriou JM; Wood D; Zheng MH
    J Cell Biochem; 2003 Apr; 88(6):1256-64. PubMed ID: 12647307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of osteoclast vacuolar H(+)-ATPase.
    Farina C; Gagliardi S
    Curr Pharm Des; 2002; 8(23):2033-48. PubMed ID: 12171517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmalemmal vacuolar-type H+-ATPase in cancer biology.
    Sennoune SR; Luo D; Martínez-Zaguilán R
    Cell Biochem Biophys; 2004; 40(2):185-206. PubMed ID: 15054222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.